Related Experiment Video
Updated: Jan 16, 2026
07:08
A High Throughput, Multiplexed and Targeted Proteomic CSF Assay to Quantify Neurodegenerative Biomarkers and Apolipoprotein E Isoforms Status
Published on: October 20, 2016
8.2K
Boosting Sensitivity through a Multianalyte Cerebrospinal Fluid Approach for Diagnosis, Prognostication, and Immune
Hannah K Weiss1, Camila S Fang2,3, Daniel A Orringer1
1Department of Neurosurgery, NYU Langone Health and NYU Grossman School of Medicine, New York, New York.
Cancer Discovery
|October 6, 2025
Abstract
None:
The CSF-BAM assay, developed by Pearlman, Wang, and colleagues, integrates the detection of somatic mutations, genome aneuploidy, and B- and T-cell receptor clonality from a single cerebrospinal fluid DNA library to increase the sensitivity of cerebrospinal fluid to diagnosis and track brain tumors. See related article by Pearlman et al., p. 2002.
